Neutrophil Extracellular Traps: A Potential Therapeutic Target in MPO-ANCA Associated Vasculitis?

Kim M. O’Sullivan* and Stephen R. Holdsworth

1 Department of Medicine, Centre for Inflammatory Diseases, Monash University, Clayton, VIC, Australia, 2 Department of Nephrology, Monash Medical Centre, Clayton, VIC, Australia, 3 Department of Immunology, Monash Medical Centre, Clayton, VIC, Australia

Our understanding of immune recognition and response to infection and non-infectious forms of cell damage and death is rapidly increasing. The major focus is on host immunity and microbiological invasion. However, it is also clear that these same pathways are important in the initiation and maintenance of autoimmunity and the damage caused to targeted organs. Understanding the involvement of cell death in autoimmune disease is likely to help define critical pathways in the immunopathogenesis of autoimmune disease and new therapeutic targets. An important immune responder cell population in host defense and autoimmunity is the neutrophil. One autoimmune disease where neutrophils play important roles is MPO-ANCA Microscopic Vasculitis. This is a severe disease that results from inflammation to small blood vessels in the kidney, the glomeruli (high blood flow and pressure filters). One of the best studied ways in which neutrophils participate in this disease is by cell death through NETosis resulting in the discharge of proinflammatory enzymes and nuclear fragments. In host defense against infection this process helps neutralize pathogens however in autoimmunity NETosis results in injury and death to the surrounding healthy tissues. The major autoimmune target in this disease is myeloperoxidase (MPO) which is found uniquely in the cytoplasm of neutrophils. Although the kidney is the major organ targeted in this disease MPO is not expressed in the kidney. Autoantibodies target surface MPO on activated circulating neutrophils resulting in their lodgment in glomerular capillaries where they NETose releasing extracellularly MPO and nuclear fragments initiating injury and planting the key autoantigen MPO. It is the cell death of neutrophils that changes the kidney from innocent bystander to major autoimmune target. Defining the immunopathogenesis of this autoimmune disease and recognizing critical injurious pathways will allow therapeutic intervention to block these pathways and attenuate autoimmune injury. The insights (regarding mechanisms of injury and potential therapeutic targets) are likely to be highly relevant to many other autoimmune diseases.

Keywords: ANCA, glomerulonephritis, cell death, NETs, MPO
INTRODUCTION

Anti Neutrophil Cytoplasmic Antibody (ANCA) associated vasculitis (AAV) is an autoimmune disease characterized by inflammation of the small blood vessels. AAV can be divided into three different clinical categories: Microscopic polyangiitis (MPA), Granulomatosis with polyangiitis (GPA), and Eosinophilic granulomatosis with polyangiitis (EGPA). A common clinical feature between all 3 vasculitides is a loss of tolerance to neutrophil enzymes, myeloperoxidase (MPO), and proteinase 3 (PR3) which results in the generation of ANCA to either MPO or PR3. MPA patients have a high incidence of MPO-ANCA development and is more prevalent in the Asia pacific region. GPA is the dominant clinical subtype of AAV north of the equator. GPA patients have a higher incidence of PR3-ANCA.

The major organ effected is the kidney (more frequently observed in MPA disease) often resulting in rapidly progressive crescentic glomerulonephritis (RPCGN), which has the worst outcome. If left untreated 90% of patients will progress to renal failure and eventual death. Patients present with general fatigue, elevated temperature, flu-like symptoms accompanied with weight loss and diminished appetite (1, 2). These symptoms result from systemic inflammation and loss of kidney function. Extra renal symptoms are common and often characteristic and particular to their specific disease. Until the introduction of nitrogen mustard based immunosuppression most notably cyclophosphamide, treatment was primarily based on high doses of glucocorticoids. Prior to this regimen most patients would progress to end stage renal failure within 5 months (3–6). With discovery of ANCA as a diagnostic marker in the 1980s and with current treatment, remission can now be induced within 6 months and survival rates have increased to approximately 75% of patients at 5 years. Although these treatment regimens are largely successful, relapse rates remain high at around 50% at 5 years. Despite maintenance therapy, the high percentage of relapses suggest that standard treatment does not actually completely delete the pathogenic autoimmunity. The toxicity of the treatment itself contributes significantly to morbidity and mortality (3–6). Drug-related toxicity and adverse effects will cause difficulty in over 90% of patients. The most common form of death within the first year of contracting the disease will be infection associated with the immunosuppressed state of the patient. Prolonged use of cyclophosphamide is also associated with an increase rate of malignancy (7).

There is an unmet need for more specific treatment to treat the underlying immunopathology in AAV. Teasing out the underlying pathogenic mechanisms of directing AAV is essential for the development of effective treatment strategies. A key pathological feature of MPO-AAV is the accumulation of dying neutrophils. Neutrophil cell death releases the key autoantigens in ANCA associated vasculitis (AAV); myeloperoxidase (MPO) and proteinase 3 (PR3). Alongside MPO and PR3 one of the key molecules released during cell death is double stranded deoxyribonucleic acid (dsDNA). Without the protection of the cell membrane dsDNA activates multiple sensors and signaling pathways, amplifying inflammation. This review will evaluate the contributing role of Neutrophil Extracellular Traps (NETs) to the pathogenesis of MPO-AAV, with a focus on the activation of NETs, the deposition of NET derived antigens and danger associated molecular patterns (DAMPs) and the development of new experimental NET inhibitors which show promise in attenuating pathological damage to the kidney.

OVERVIEW OF THE PATHOLOGY OF ANCA ASSOCIATED VASCULITIS

AAV is a disease of unknown etiology. The pathogenesis of AAV is complex and involves a wide range of pathogenic processes. In the case of MPO-AAV and PR3-AAV there is a loss of immunological tolerance to neutrophil enzymes MPO and PR3, this in turn generates ANCA and MPO specific T cells. Neutrophil priming and activation via C5a and C5aR interactions exteriorise MPO (or PR3) on their cells surface which MPO-ANCA (or PR3 ANCA) binds to, these neutrophils home to the microvasculature of the glomeruli via selectins, P, E, and L which play a role by reducing the speed of the neutrophil in the circulation which allows it to roll. The second signal comes from the neutrophil surface integrins β1 and β2 which interact with the ICAM-1 and ICAM-2 ligands on the inflamed endothelium, the rolling neutrophils slow down, and crawl along the endothelium mediated by integrins to the site of transmigration from the capillaries into the interstitium. Neutrophils either degranulate or release neutrophil extracellular traps (NETs, to be discussed in detail in a later section), causing direct injury through the release of enzymes, reactive oxygen species (ROS), and proteases. Excess neutrophils, MPO specific T cells, and macrophages [via a delayed type hypersensitivity (DTH) mechanism] are recruited resulting in a vicious cycle of injury which causes glomerular injury (8) (see Figure 1).

NEUTROPHIL ACTIVATION IN MPO-AAV

The first in vitro experiments demonstrating the potential pathogenicity of ANCA came from the laboratory of Falk et al., where it was demonstrated that neutrophils can be activated by ANCA (9). Purified ANCA sera from patients with pauci-immune necrotizing and crescentic GN incubated with normal...
human neutrophils, induced a reactive oxygen species burst (ROS) followed by degranulation of the neutrophil. Further flow cytometry studies demonstrated that after priming neutrophils with the cytokine tumor necrosis factor (TNF) neutrophils exteriorized MPO to the cell surface. The surface location of MPO allowed interaction with ANCA.

Brouwer et al. (10) further demonstrated both in vitro and in vivo that the numbers of activated neutrophils within kidney biopsies of patients with Wegener’s granulomatosis correlated significantly with serum creatinine levels taken at the time of biopsy (22 PR3 positive and 5 MPO positive) (10). All ANCA samples from patients (n = 19) were capable of activating primed neutrophils, however no correlation was observed between the ANCA titer of patients and the numbers of activated neutrophils within renal biopsies. A major deficiency of the hypothesis that ANCA induced renal disease was the fact that the key autoantigens, MPO and PR3 were not expressed in the kidney, the major organ damaged by autoimmunity to these antigens. This was also the first study to demonstrate the presence of neutrophil enzymes MPO, PR3 and elastase (HLE) extracellularly within renal biopsies. Their deposition occurred when neutrophils were trapped in the glomerular capillaries where degranulation and other forms of neutrophil cell death released these autoantigens extra-cellularly into the kidney. This initiates injury, attracting anti MPO/PR3 T cells driving Delayed Type Hypersensitivity (DTH) effector responses which also induces further neutrophil attraction. In summary neutrophils play an essential role in converting the kidney from innocent bystander status to secondary target status where deposited MPO within the kidney is recognized as an antigen by MPO specific T and B cells.

A major advance in confirming the unique pathway and role of renal targeting by neutrophils was an experiment by the Falk and Jennette group using neutrophil depleted mice. These mice could develop anti-MPO autoimmunity but they could not develop GN unless neutrophils were infused into their circulation. Exogenous neutrophil infusions allowed the development of anti MPO vasculitis and GN confirming the non-redundant role played by neutrophils in the disease (11, 12).

Studies in human ANCA demonstrated that ANCA IgG binds to the MPO or PR3 expressed on the surface of human neutrophils and ligates the Fragment Crystalline gamma RIa receptor (FCyRIa). Porges et al. demonstrated that blockade of the FCyRIa with a monoclonal antibody significantly reduced the production of ROS of ANCA activated neutrophils (13). Binding of ANCA to the FCyRIa receptor may be one mechanism in which human neutrophils activate signal transduction pathways which result in inflammation (13).

In addition to FCyRIa other studies have also shown a role for FcyRIIib in ANCA activation of neutrophils. Kocher et al.
demonstrated that FcγRIIA requires a high density of ANCA binding whereas FcγRIIB is expressed at 10x higher density than FcγRIIA on the cell surface of neutrophils (14). These results are indicative of FcγRIIB being involved in the initial engagement by ANCA and that cross linking of the FcγRIIB favors adhesion of activated neutrophils to the endothelium.

Further in vitro studies demonstrated the role of cytokines in priming neutrophils for ANCA activation. Kettritz et al. further confirmed the requirement of cytokine priming of neutrophils with TNFα showing the translocation of both MPO and PR3 to the cell surface. Studies of both the binding and activating properties of ANCA, indicated that both intact ANCA and the F(ab)_2 portion of the Ig could cross link MPO or PR3 on the membrane surface of neutrophils (15). ANCA binding alone was not sufficient enough to activate neutrophils, crosslinking of either MPO or PR3 on the cell surface was required to induce a ROS burst.

**Complement Activation of Neutrophils in AAV**

The complement system is comprised of 3 distinct pathways, the classical, lectin, and alternative pathway all of which produce effector molecules used to fight infection. All 3 pathways initiate a complement cascade converging to form C3 and C5 convertases. The resulting complement cascade generates C5a which binds to the C5aR1 and C5aR2. C5aR1 is expressed on multiple immune cells, including neutrophils and monocyte/macrophages. Cleavage products of the complement cascade (C3a and C5a) are seen by the immune system as danger signals, and recruit further cells of the immune system, in particular neutrophils.

In the context of AAV, evidence suggests that C5a-C5aR interactions are pathological. C5a can prime neutrophils for NET formation, recruit neutrophils to the vascular bed of the glomeruli, and enhance Dendritic cell activation (16). Multiple animal studies of AAV have shown that the alternative pathway plays a critical role in priming neutrophils for activation by ANCA via signaling through C5a-C5aR1 interactions (16–18). Complement activation factors are increased in patients with active AAV disease. These observations suggested that C5a may be a therapeutic target in AAV. Inhibition of the C5aR1 with the antagonist CCX168 (Avacopan) has been demonstrated in phase II and III clinical trials to be effective in modifying disease severity in patients with active AAV (19–22).

**NEUTROPHIL EXTRACELLULAR TRAPS (NETS)**

A novel mechanism by which neutrophils kill microorganisms was discovered by Brinkmann et al. (23). This study demonstrated that activated neutrophils were able to produce extracellular traps containing DNA fibers, coated with neutrophil proteins from the primary granules (MPO, NE, cathepsin G), secondary granules (lactoferrin), tertiary granules (MMP9), and histones (H1, H2A, H2B, H3 and H4 and the H2A-H2B DNA complex). This seminal study suggested that neutrophils produce NETs to amplify the effectiveness of their antimicrobial granules by producing a large net in a concentrated area, which formed both an antimicrobial and physical barrier to prevent the spread of microorganisms. The authors of this study very insightfully suggested that this mechanism may also have a detrimental effect on the host that could stimulate autoimmunity (23). This initial work, opened a new field in neutrophil biology that in the last 16 years has expanded to define, the signaling pathways for NET production, identification methods of NETs, and a role for NETs in perpetuating inflammation in autoimmune diseases. NETosis is a powerful inducer of injury and therefore a major potential therapeutic target.

**Sequence of Events Required for NETosis**

NET formation is a unique form of neutrophil cell death that it is not instigated by either necrosis or apoptosis. Live cell imaging of NETs by Fuchs et al. revealed the basic steps required for NET formation (24). PMA stimulated peripheral neutrophils from healthy donors were imaged for 240 min, and the steps in NET formation were outlined to follow a pattern: Firstly 60 min after stimulation, neutrophil nuclear lobules begin to lose their shape, the nuclear envelope begins to disintegrate into small vesicles and chromatin decondensation begins with segregation of euchromatin and heterochromatin, 180 min after stimulation the nuclear envelop has completely disintegrated, granular membranes rupture and the decondensed chromatin mixes freely with both the contents of the granules and cytoplasmic material, then the outer cell membrane ruptures and a protrusion of a net like structure comprised of DNA, histones, MPO, and NE is extruded (see Figure 2). The authors through elegant experiments determined that this form of cell death was neither apoptosis nor necrosis as DNA fragmentation a key marker in apoptosis was absent via TUNEL staining in NET formation. Necrotic cells did not make NETs, their nuclear membranes did not rupture, and the nucleus just fused into a homogenous mass with no apparent segregation of euchromatin and heterochromatin (24).

**NETosis Requires ROS**

Reactive oxygen species (ROS) are required for the formation of NETs. The most compelling evidence comes from patients with Chronic Granulomatous Disease (CGD) who have genetic deficiencies that cause mutations in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. CGD patients are unable to form ROS and as a result are unable to make NETs (24). CGD patients suffer from recurrent bacterial and fungal infections that they are unable to clear infection efficiently due to the lack of NADPH which is required for phagocytosis by granulocytes. Addition of H_2O_2 to CGD patients’ neutrophils in vitro enables neutrophils to produce NETs, suggesting that the sequence of events that allows NET formation can be restored downstream of NADPH (24).

**Role of Peptidyl Arginine Deiminase (PAD4) in the Citrullination of Histones**

One of the determining factors that distinguishes between neutrophil NET formation and either apoptosis or necrosis is the...
**FIGURE 2** | ANCA mediated neutrophil extracellular trap (NET) formation. (1) Neutrophils are primed by inflammatory mediators (such as TNFα, LPS, IL-8, or C5a), which exteriorises MPO on the cell surface (2) ANCA antibody recognize MPO as their cognate antigen and bind to the surface of the neutrophil which initiates a ROS burst (3) NE, PR3, and MPO migrate to the nucleus where they break down the nuclear envelope (4) Increased PAD4 expression facilitates citrullination of histones, the contents of the nucleus and cytoplasm mix as DNA decondenses (5) Neutrophil elastase breaks down actin fibers of the neutrophil cytoskeleton (6) DNA is released with MPO, PR3, ROS and citrullinated histones.

citrullination of histones mediated by PAD4. Initial observations of the role of PAD4 and its association with deimation of histones in neutrophils came from experiments in animal models of rheumatoid arthritis where the expression of PAD4 and citrullinated histones correlated with an increase in disease severity (25). Neeli et al. observed in experiments with stimulated human neutrophils that NET formation was associated with deimation of H3, whereas apoptotic cells produced no deimation of H3, making citrullination of H3 a novel marker to distinguish between NET formation and apoptosis (26). To investigate further the requirement of PAD4 in the citrullination of histones in NET formation Wang et al. demonstrated that the inhibition of PAD4 by the pan PAD inhibitor Cl-amidine failed to produce NETs in HL-60 granulocytes, through the inhibition of H3 citrullination (27). The same group followed up these experiments in PAD4+/− mice and demonstrated that PAD4 was required for NET mediated efficient bacterial killing. Neutrophils stimulated to form NETs by LPS, PMA, and H2O2 in vitro all required PAD4. PAD4−/− neutrophils were unable to form NETs in response to any of the stimuli. Using a model of necrotizing fasciitis the authors demonstrated that PAD4−/− mice were unable to produce NETs and had a reduced capacity to clear bacterial infection compared with PAD4+/+ mice (28).

**Critical Enzymes and Molecules Required for NETosis**

Both NE and MPO are stored in the primary (azurophilic granules) of neutrophils, and are both found abundantly adhered to NET fibers. Experiments by Papayannopoulos et al. demonstrated that translocation of NE to the nuclear envelope was required for the decondensation of chromatin (29). After the initial ROS burst NE is released from primary granules where it migrates to the nucleus and digests nucleosomal histones, ultimately instigating the decondensation of the chromatin. MPO was also found to bind to chromatin and enhance decondensation independent of its enzymatic functions. The role of MPO in NET formation was further explored in subsequent experiments and neutrophils from 100% MPO deficient individuals were shown to be unable to form NETs (30). Interestingly neutrophils from individuals with only a partial MPO deficiency were still able to make NETs. MPO contributes 5% of the dry weight of neutrophils and is the most abundant neutrophil granzyme. MPO generates hypochlorous acid through the oxidation of chloride and halide ions in the presence of H2O2, this is highly antimicrobial. Despite the requirement of MPO to generate NETs and its highly effective antimicrobial properties, a genetic deficiency in MPO does not appear to have a major
impact on individuals with this defect, they generally live healthy lives unless they have co-morbidities such as diabetes (31).

The importance of MPO in regulating ROS was determined by demonstrating that MPO inhibitors successfully blocked PMA induced NET formation, and that this process could not be rescued downstream by adding extracellular MPO (32). Observations by other laboratories suggest the requirement for MPO in NET formation may be dependent on the activating stimulus. Neither ROS nor MPO is required for NET formation when triggered by Leishmania parasites, but NE was required (33). These findings were in agreement with experiments by Parker et al., who found that MPO was required for NET formation when stimulated by PMA but not by S. aureus and E. coli (34). Overall these experiments highlight the need for physiological relevant experiments, although PMA is a potent NET inducer, it is not found physiologically in either humans or mice and caution should probably be used when using it to study signaling pathways, and assessing requirements for enzymes and ROS, as they may not be representative of what happens in vivo.

Role of Gasdermin D in NET Formation

Pyroptosis is a lytic form of inflammatory cell death where Gasdermin D (GSDMD) plays a critical role in forming pores that allow the influx of water resulting in swelling of the cell and osmotic lysis (35). Recently GSDMD has been implicated in having a crucial role in the formation of NETs.

During a large screening of small molecule inhibitors of NETosis Sollberger et al. identified a compound LDC7559 with a pyrazolo-oxazepane scaffold that binds to GSDMD preventing NETosis (36). Using LDC7559 to inhibit NET formation it was demonstrated that neutrophil elastase (NE) and GSDMD work together to break down the nuclear envelope and again to break down the cell membrane at point of expulsion of the DNA webs. LDC7559 inhibits NET formation at low concentrations (1 μM) without blocking phagocytosis, ROS production, NE or MPO activity. These attributes of LDC7559 have potential as therapeutic treatment of diseases with excessive NET burden as it will prevent NETosis whilst keeping host defense intact. This work further consolidated the critical role of NE in NETosis as NE is essential for the activation of GSDMD. This highlights both NE inhibitors and GSDMD as potential therapeutic benefit in inhibition of NETs in inflammatory diseases (29, 30, 36).

Amongst the first hypothesized steps in NETosis we can now add the role of GSDMD (24). The accepted chain of events are: (1) the neutrophil undergoes a ROS burst, followed by (2) migration of neutrophil enzymes NE and MPO to the nucleus where NE induces break down of the nuclear envelope via cleavage and activation of gasdermin-D that punches holes in the nuclear membrane, (3) increased PAD4 expression facilitates citrullination of histones and decondenses DNA, (4) NE destabilizes the structure of chromatin and modifies histones and cleaves actin within the cytoskeleton weakening the outer cell membrane to allow, (5) expulsion of the NET.

Caspase 11 Driven NETosis

Traditionally defined NETosis requires citrullination of histones via PAD4, neutrophil elastase and to a limited extent MPO. A recently discovered form of NETosis driven by detection of cytosolic LPS activates caspase 11 and occurs independently of the requirement of traditional neutrophil enzymes. Inhibition of MPO, NE and PAD4 does not inhibit caspase 11 mediated NETosis (37). This mechanism is thought to have evolved to enhance gram negative bacteria killing by releasing antimicrobial NETs of DNA. Inhibition of both GSDMD and caspase 11 blocks NETosis. Release of MPO and NE is inhibited, which suggests that GSDMD is most likely to be involved in creating pores in the membranes of lysosomes which are responsible for liberating MPO and NE (37). Caspase 11 and GSDMD work in partnership to facilitate NETosis in two stages of NETosis. In stage 1 GSDMD creates pores in the nuclear membrane allowing caspase 11 to enter and cleave histones allowing chromatin relaxation for NET extrusion. In stage two GSDMD creates pore in the cell membrane to allow release of the DNA (37).

Although this type of NETosis is thought to have evolved to defend neutrophils against the invasion of gram negative bacteria, there are other implications where this may be relevant in other diseases. Both GSDMD and caspase 11 may be potential therapeutic targets.

Signaling Pathways in NET Formation

Several different pathways have been reported to play functional roles in NET formation. The first of these pathways is known as the Raf (rapidly accelerated fibrosarcoma), MEK-(mitogen-activated protein kinase), ERK (extracellular signal-regulated kinase pathway). The Raf-MEK-ERK pathway is responsible for controlling the expression of the anti-apoptotic protein Mcl-1. PMA stimulated neutrophils downregulate Mcl-1 immediately after stimulation, which blocks apoptosis and favors NET formation. PKC, cRaf, and MEK inhibitors can block this downregulation, suggesting that the Raf-MEK-ERK pathway is responsible for controlling NET formation. The authors of this study suggest this pathway could be a potential therapeutic target in diseases where aberrant NET formation occurs (38).

There has been speculation that NET formation could also be activated by the same pathway that causes necroptosis in neutrophils. Necroptosis is another form of cell death distinct from apoptosis. It is considered to be a programmed form of necrosis. The simplified version of the complex signaling pathway is that once activated a series of signals cause interaction between RIPK3 (receptor interacting protein kinases-3) which phosphorylates MLKL (mixed lineage kinase domain-like), which creates a conformational structural change allowing the oligomerization of MLKL to form a pore, which results in increased osmotic pressure within the cell as ion and water enter the cell resulting in rupture of the cell membrane. Experiments using Ripk3−/− mice and MLKL inhibition demonstrated that this pathway is used downstream of ROS production (39). Nec-1 an inhibitor of necroptosis, which prevents the formation of the necrosome through the modulation of RIPK1 and the subsequent phosphorylation of RIPK3 and MLKL, prevented the formation of NETs induced by PMA or monosodium urate (MSU) crystals in both human and mouse neutrophils. In direct contrast, Amini et al. found that NET formation occurred independent of signaling through RIPK3 and MLKL (40). Using
the neutrophils from the genetically modified mice deficient in Ripk3 and human neutrophils chemically inhibited with the MLKL inhibitor necrosulfonamide (NSA), the authors conclude that NET formation is independent of a necroptotic form of death. The notable difference between these 2 studies could be dependent on the different stimuli used to activate and stimulate NET formation. Desai et al. used MSU crystals, and PMA whereas Amini et al. used GM-CSF primed neutrophils with C5a, LPS, or E. coli.

ANCA mediated NETosis can be mediated by the RIKP1/3 MLKL pathway (22). In vivo NETs can be pharmacologically inhibited using the RIPK1 inhibitor Nec-1s, and the MLKL inhibitor necrosulfonamide (22). RIPK3 and MLKL deficient mice are protected from the development of necroting crescentic glomerulonephritis induced by anti-MPO antibody. RIPK3 deficient bone marrow (BM) transfers, in the same animal model were protected suggestive of necroptosis playing a critical role in the progression of necroting crescentic glomerulonephritis.

MPO Is Biologically Active in NETs
The bactericidal capacity of MPO in NETs has been shown in vivo to be biologically active when adhered to DNA remnants from NET formation. Parker et al. measured the peroxidase activity of MPO released from NETs, and found that over 80% of the MPO released from the neutrophil came from NET formation, and was still biologically active (34). The findings of these experiments have two implications. Firstly, MPO adhered to NETs may aid in the bactericidal capacity of NETs and increase the role of neutrophils role in reducing the spread of bacteria at sites of infection. The second implication, is that the extracellular NET MPO that is deposited is biologically active and may cause direct injury to the surrounding tissues and also become available as an autoantigen in autoimmune in AAV.

NETs Transfer Neutrophil Antigens in AAV
Although the role of NETs in enhancing host defense against bacterial infection has been well-established, the production of NETs also has potential to expose the immune system to potential self-antigens, and therefore may play a role in perpetuating inflammation by triggering and enhancing injurious autoimmune to extracellular MPO.

Proof of concept that NETs can initiate and enhance autoimmune in AAV comes from animal models of the disease. Sangarelli et al. demonstrated that neutrophil antigens from NETs can be transferred to dendritic cells (DCs) (41). Live cell imaging of stimulated pro inflammatory neutrophils co-cultured with myeloid DCs (mDCs) showed that NET forming neutrophils make stable connection with mDCs, whilst apoptotic neutrophils only form infrequent contact with mDCs. To examine the possibility of the transfer of the auto-antigens MPO and PR3 from dying neutrophils to mDCs, co- cultures of neutrophils and mDCs were observed and the efficacy of neutrophil antigen transfer characterized. Necrotic cells failed to transfer either MPO or PR3. These auto-antigens were internalized by the DCs with apoptotic bodies less frequently than MPO or PR3 from NET forming neutrophils. Addition of DNase I to the coculture media prevented the transfer of NET associated antigens, by disintegrating the DNA back bone of the NETs, indicating that the intact DNA structure is required for successful transfer of the autoantigens. Based on these findings the authors of this study transferred the mDCs cultured with either NETs or apoptotic neutrophils into mice via intraperitoneal injection, weekly for a period of 6 weeks, collected serum and examined both the kidneys and lungs for pathology at the termination of the experiment 4 months later. Results demonstrated that the mDCs co-cultured with the NET forming neutrophils had an increased production of circulating ANCA, IgG, and C3 deposition, and an increased kidney pathology score compared to the apoptotic neutrophils co-cultured with mDCs, which had a reduced amount of ANCA production and no evidence of vasculitis in either the lungs or kidneys.

This study provided proof of concept that NET forming neutrophils can initiate vasculitis. The authors conclude that AAV skew neutrophil cell death toward NETosis rather than apoptosis. They also confirm that apoptotic cell death is more likely to protect from excessive inflammation and the development of autoimmunity. The authors do not discuss the possibility that apoptotic neutrophils co-cultured with mDCs may actually have a protective effect. This has been reported in other diseases such as type 1 diabetes (42). DCs co-cultured with apoptotic bodies from β cells and injected into mice have been shown to induce a reduction in co-stimulatory molecules and production of cytokines in NOD diabetic mice (42).

NETs not only exposed the autoantigens MPO and PR3 but also make histones available for interaction with the immune system. Histones themselves elicit strong responses from the immune system by activating danger associated molecular patterns (DAMPS), recognized in particular by toll-like receptors (TLR) 2, TLR4, and nucleotide-binding oligomerisation domain like (NOD) receptors. Histones have been implicated in enhancing injury in many other forms of disease such as sepsis, trauma associated lung injury, sterile liver injury, and kidney injury (43–47).

Histone capacity to induce inflammation and injury is supported by the actions of PAD4. A recent study by Kumar et al. found that inhibition with the PAD inhibitor Cl-amide or histone antibody depletion, reduced glomerulonephritis in a mouse model of anti GBM (48). A reduction in glomerular crescents, and leukocyte infiltration was significant, indicating that targeting extracellular histones could be an effective treatment in glomerulonephritis.

NET Interactions With T Cells
NETs have an established role in innate immunity, but less is known about their interactions with the adaptive immune system. In vitro studies of human NETs and T cells have indicated that NETs can prime CD4+ T cells by decreasing their activation threshold (49). Co-culture of T cells and NETs alone increases the upregulation of the T cell activation markers CD25 and CD69, but does not increase T cell proliferation. Co-cultures of DCs, T cells and NETs, results in an increase in the activation of T cells, measured by the increased production of T cell...
proliferation cytokines IFNγ, IL-17A, IL-4, IL-10, and IL-2. This effect however is not seen when NETs alone are cultured with T cells, or in transwell plates where the DCs and NETs are separated from the T cells, indicating that T cell direct contact with both DCs and NETs is required for T cell activation (49).

In vivo studies of NETs indicate they can activate Th17 cells, indirectly by priming human macrophages and in a murine model of atherosclerosis (50). Co-cultures of monocytes with NETs activated by cholesterol crystals resulted in an increased production of monocyte cytokines (including IL-1β). In a model of murine atherosclerosis, NETs were found associated with atherosclerotic lesions, which could be reduced when disease was triggered in NET deficient mice (ApoE, PR3, and NE deficient) to prevent NET formation. The production of IL1β by macrophages increased the secretion of T cell derived IL17, and subsequent neutrophil recruitment to vascular endothelia (50).

**Complement and NET Interactions**

Neutrophils from either C3−/− or C3a receptor−/− (C3aR) mice are unable to form NETs (51, 52). This indicates that complement is non-redundant in initiating NETosis. Activated neutrophils express complement factors such as C3 and properdin and Factor B on their cell surface- all components of the alternative complement pathway (53). In host defense neutrophils form NETs to increase bactericidal killing by increasing their surface area in which they ensnare bacteria. Complement opsonization of bacteria have an enhanced ability to induce NETosis (54). C5a both recruits neutrophils and primes them for NET induction through upregulation of Toll-like and complement receptors (55). Neutrophil enzymes contained with the DNA fibers of NETs have the capacity to cleave C3 and C5 into active fragments. For example MPO can cleave C5α and C5b, whereas Neutrophil Elastase can cleave C3 in to C3a and C3b (56, 57).

**OBSERVATIONS OF NETS IN CLINICAL AAV**

Kessenbrock et al. provided the first data that indicated a possible pathological role for NETs in AAV. ANCA IgG from patients with small vessel vasculitis (SVV) were able to trigger NET formation in isolated human neutrophils from healthy individuals primed with TNFα (23% of neutrophils formed NETs), whereas IgG from normal healthy individual was only able to stimulate 11% of neutrophils to form NETs. The main autoantigen targets MPO and PR3 were both present upon the NET DNA fibers and were still accessible for ANCA Ig to bind to. After establishing that ANCA could activate NET formation and that the auto antigenic targets MPO and PR3 were accessible within the NETs the authors sought evidence of in vivo NET formation in the biopsies of AAV patients. Using antibodies to NET components (DNA, histones, MPO, NE, PR3, and LL37), they found that NETs were present in 9/15 biopsies examined (58).

We have demonstrated that NET formation is closely associated with the deposition of MPO in glomeruli in a large clinical study of MPO-AAV patients (n = 47) (59). Extracellular MPO was significantly higher in glomeruli with NETs. This was also the first study to demonstrate the presence of macrophage extracellular traps (METs) that were MPO positive and frequently observed within the glomeruli of MPO-AAV patients (59). Considering macrophages are one of the prevalent leukocyte subtypes infiltrating glomeruli in AAV biopsies, potential therapies targeting NETs should also extend to METs.

Further studies of NET involvement in AAV patients include case reports demonstrating NET formation through the use of antibodies against MPO, Citrullinated Histones and PAD4 or using DAPI in combination with MPO to identify NETs (60, 61). A larger study containing 15 AAV patients (for peripheral neutrophil studies) and 6 kidney biopsies in China showed similar results to the Kessenbrock et al. study, demonstrating enhanced NET formation in patients with AAV compared to healthy controls. There was evidence of increased NET formation in the biopsies of patients with active crescentic GN but minimal NET evidence in the non-crescentic patients providing evidence that NETosis maybe injurious.

Attempts have been made by several research groups to show an association between circulating NET markers and active disease. In a large cohort of 93 AAV patients Soderberg et al. (62), found that patients with active AAV had significantly more remnants of NETs than healthy controls within their circulation. No difference was found between patients in remission and healthy controls. In contrast, Wang et al. found the level of circulating Neutrophil extracellular traps did not correlate with disease activity. In this cohort there were 34 patients with active AAV and 63 patients with AAV in remission (63). A significant difference in the numbers of circulating NETs between AAV patients and healthy controls was determined using circulating cell free DNA (cfDNA) as a marker of NETs. There was no correlation between NET formation in the circulation of patients with active disease when compared to patients in remission.

Wang et al. investigated the levels of DNase I an enzyme that specifically degrades DNA and found that patients with AAV had significantly higher circulating levels of DNase I than healthy controls whereas there was no observed difference between the active AAV and remission group. Taken together current data does not suggest that the presence of NET remnants in the serum is a reliable indicator for disease severity or activity (63).

More recently it has been shown that NET formation can occur in AAV independent of ANCA (64). In a cohort of 99 AAV patients, patients’ neutrophils isolated from whole blood demonstrated excessive NET formation ex vivo when stimulated with ANCA serum depleted of IgG. Serum levels of ANCA did not correlate with NET remnants, however increased NET formation was observed in patients with active disease. Of interest patients with MPO-AAV had significantly more NET formation than those of PR3-AAV patients. Neither C5αR inhibitors or eculizumab were able to prevent formation of NETs ex vivo, indicating that C5α-C5αR interactions are not critical for human NET formation ex vivo. Whereas, a genetic deficiency in either C5α or C5αR prevents NET formation in murine neutrophils (as discussed earlier).
NET formation in AAV is distinct from NET formation observed in systemic lupus erythematosus (SLE). Serum from $n = 80$ AAV patients and $n = 59$ SLE patients, were incubated with healthy circulating neutrophils, and induced excessive NET formation. AAV patient serum significantly induced more NETs compared to serum from both healthy controls and SLE patients (65). The qualitative appearance of NETs from AAV patients also differed from SLE patients. AAV induced NETs were lytic in nature with large expulsion of DNA, and occurred much slower than that of SLE induced NETs which were faster, with less expelled DNA, a higher concentration of mitochondrial DNA (mtDNA) and less lysis of the cell membrane. These results should be interpreted with caution as they were performed ex vivo by incubating patient serum with healthy neutrophils. A more efficient way of determining the difference between AAV and SLE NETs would be to conduct the same experiment with the neutrophils from the patients. As previously mentioned AAV neutrophils have a higher propensity to NET than those of healthy neutrophils, therefore data collected from neutrophils form healthy patients and SLE patients may not behave in the same manner (62).

Collectively these disparate results indicate using circulating NETs is not a good biomarker for AAV disease activity. Observations from ex vivo experiments may not be representative of what happens in vivo. Detection of NETs in kidney biopsies would provide more relevant evidence of pathogenicity as these are the sites of direct injury opposed to measuring NET remnants from the circulation in serum, or inducing NET formation ex vivo.

## VITAL NETS AND MITOCNDRIAL DNA RELEASE

Neutrophils are also able to produce NETs which do not ultimately end in death of the neutrophil. This has been termed “vital NETosis,” and uses some of the same pathways as traditional “suicidal NETosis,” such as the translocation of NE to the nucleus, activation of PAD4 and decondensation of chromatin. Instead of extruding all the nuclear contents as in suicidal NETosis, in vital NETosis, the DNA is released within vesicles, and the neutrophils phagocytic functions remain intact (51). In vivo imaging of neutrophils during gram-positive skin infections, have demonstrated that NET forming neutrophils can still effectively crawl despite being anuclear, and still have the ability to kill bacteria via phagocytosis (51).

Mitochondrial (mt) NETosis has also been observed, like normal NETosis it is ROS dependent. Mitochondrial nets have been formed in vitro in response to stimulation by GM-CSF and C5a (66). Recently mitochondrial NETosis has been demonstrated in low density neutrophils from lupus nephritis patients (67). The mitochondria formed NETs were pro-inflammatory and were able to induce production of type 1 interferons. Using MRL/Ipr (lupus prone mice), it was shown that the in vivo administration of MitoTEMPO an inhibitor of mitochondrial ROS was able to reduce NETosis, and ameliorate autoimmunity in the MRL/Ipr mice (67).

## RELEASE OF DNA FROM OTHER LEUKOCYTES OTHER THAN NEUTROPHILS IS PROINFLAMMATORY

Neutrophils are not the only cells that release DNA. It has been recently described that activated CD4 T cells can release extracellular DNA traps (68). Ex vivo cultured Human CD4 T cells and naive CD4+T cells from mice produced DNA threads when activated with anti-CD3/antiCD28 antibodies for 24 h. The DNA released is highly oxidized, coated with histones similar to what is seen in the generation of NETs. The expelled DNA from CD4+T cells, was also detectable in vivo in the lymph nodes of EAE mice. The generation of these T cells is dependent on the generation of reactive oxygen species (ROS). Using the mitochondrial ROS inhibitor SkQ1 at a low dose in vivo reduces excess mitochondrial ROS and is protective in a model of EAE. Antigen specific (MOG35–55) ex vivo stimulation of lymph node cells from mice treated with SkQ1 had reduced immune responses and reduction in pro-inflammatory cytokines.

B cells release mitochondrial DNA in response to stimulation with CpG and non-CpG oligonucleotides (ODN) but no other known NET stimulators (69). This is independent of typical cell death such as necrosis or apoptosis. Unlike NETs this process is rapid, happening within minutes of stimulation, does not rely on ROS or NADPH. B cell expulsion of DNA is of mitochondrial origin and released in full size rather than fragments. B cell mt DNA release, acts like a DAMP and induces the production of Type 1 IFNs in co-cultures PBMCs. Inhibition of B cell mt DNA is not accomplished by inhibitors of other types of cell death, or by blocking ROS. The only treatment effective in blocking the release of B cell mt DNA was ZnCl2.

This data indicates when considering the inhibition of NETs, the effectiveness should be assessed also in other cells leukocytes and lymphocytes which may be contributing to inflammation through the release of ecDNA.

## NET DERIVED EXTRACELLULAR DNA IS PRO-INFLAMMATORY

One of the major components of NETs is the backbone DNA structure. Within NETs this backbone of DNA provides the substrate that the neutrophil enzymes, proteases, and histones adhere to. Although the production of NETs helps to fight infection by containing the spread of infectious bacteria, the DNA itself can cause inflammation through activation of DNA sensors, and histone exposure (as discussed in previous section). DNA is released from dying cells through several different mechanisms including apoptosis, necrosis, necroptosis, and pyroptosis. Besides the different signaling pathways involved and pathological appearance of these types of cell deaths, the size of the DNA and quantity released during death differs also.

DNA derived from NETs can activate the immune system by acting as a danger signal. The nuclear location of DNA offers protection from exposure to the immune system under normal healthy conditions. Self-DNA which is released extracellularly during either pathogenic processes or autoimmunity is seen
by the immune system as a Danger Associated Molecular Pattern (DAMP) where as non-host DNA is recognized as a Pathogen Associated Molecular Pattern (PAMPs) by Pattern Recognition Receptors (PRRs). DNA which escapes the nucleus, is detected by several different sensors. TLR9 recognition of DNA occurs within endosomes. Within the cytoplasm extra nuclear DNA is detected by either three prime repair enzymes, exonuclease 1 (TREX1), or cyclic GMP-AMP synthase (cGAS). This recognition of extra nuclear DNA activates the adapter protein Stimulator of Interferon Genes (STING). The different DNA sensors can also control which pathway of cell death may occur. For instance, extracellular DNA activation of TLR9 will induce apoptosis, activation of RIP3 will activate necrosis and NETosis, caspase 9 will trigger apoptosis, and activation of AIM2 will induce pyroptosis.

**TARGETING NETS AS THERAPY IN AAV**

There are currently no alternative proven safe therapies that can replace immunosuppressive cyclophosphamide or rituximab for the treatment of AAV. Both these treatments render patients susceptible to infection (70, 71). Cyclophosphamide suppresses bone marrow production of all leucocytes and therefore immunity is unable to be restored quickly. White blood cell counts can take weeks to return to an acceptable level leaving patients vulnerable to infection, and with a worsened prognosis upon pathogen insult. While non-targeted immunosuppression can attenuate AAV, critical functions for maintaining host immunity are compromised, resulting in severe and life-threatening side effects, specifically increased susceptibility to opportunistic infections and malignancy.

**Potential Strategies to Prevent NETosis**

Recent evidence suggests targeting some cell death pathways, particularly NETosis may be safer than conventional therapies. This is because emerging inhibitors of some critical NETosis specific enzymes have few off target effects. However, many of the potential NETosis inhibitors are reversible or have short half-lives. Early infection detection and rapid withdrawal would minimize the risk of increased susceptibility to infection. A summary table of inflammatory mediators released by NETs and pathways with potential therapeutic avenues can be found in Table 1 and experimental evidence demonstrating a pathogenic role of NETs in disease initiation/progression are summarized in Table 2.

**Peptidyl Arginase Deiminases**

There are several potential candidates for targeting NETosis as therapy in autoimmune diseases, including CI-amidine (and the second generation BB-CI amidine), both pan PAD inhibitors, DNase I which specifically targets and clears DNA and gasdermin D inhibitors which will prevent both pyroptosis and NETosis. Multiple studies have shown a protective effect in autoimmune diseases when PAD4−/− animals have been used, so it would be likely that a PAD inhibitor would have some effect in ameliorating autoimmunity in diseases in which NETs are likely to play a role such as lupus, atherosclerosis, arthritis, diabetes, and AAV (86, 87, 92–95). Although CI-amidine and BB-CI amidine which has a longer half-life in vivo has been beneficial in animal models, there are concerns that in human diseases that the inhibition of all the PADs not just PAD4 which is implicated in NET formation could have a detrimental effect in patients by increasing their susceptibility to infections. Specific inhibitors for PAD4 with no off target effects are emerging. Our laboratory has shown the use of GSK484 a specific PAD4 inhibitor and the pan inhibitor BB-CLA are protective in animal model of AAV. With a reduction in NETs, extracellular MPO and neutrophils recruitment to glomeruli. Interestingly BB-CLA is also able to induce an increase in numbers of MPO specific T regulatory cells (88).

**Deoxyribonucleases (DNase)**

The deoxyribonuclease family can be divided into two broad classes based on their biochemical structure and functional properties. The DNase I family consists of DNase I, DNase 1L1, DNase 1L2, and DNase1L3. Little is known about the functions of DNase L1, and DNase 1L2. DNase L1 is produced mainly by muscle and myocardium whereas DNase 1L2 is produced in varied sites including the brain lungs, placenta and skin. All of the DNases cleave DNA, for the purposes of this review we will concentrate on DNase I and DNase 1L3 which have both been implicated in regulating ecDNA in autoimmunity.

DNase I family enzymes require bivalent magnesium and calcium ions for activation. Without magnesium DNase I is unable to efficiently cleave DNA phosphodiester bonds. DNase I is mainly produced by the pancreas, and salivary and parotid glands and released into the blood stream. G-Actin forms a complex with DNase I and inactivates it, the biological significance of this is not yet known, however this does suggest that DNase I is subjected to regulation in vivo. DNase I preferentially degrades double stranded DNA (dsDNA) over single stranded DNA (ssDNA). The primary role of DNase I is to degrade extracellular nuclear proteins- any disruption in this process has the potential to cause autoimmunity.

DNase1L3 is expressed highly in the lymphoid organs, and has a role in promoting plasma ecDNA homeostasis. DNase1L3 enhances fragmentation of DNA and targets nucleosomes and DNA protein complexes. DNase1L3 plays a role both in intra and extracellular degradation of DNA. It has two nuclear localization signals unlike DNase 1 which only has one in the N-terminal signal. It is proposed that this is why DNase1L3 may have a role in apoptosis where it enhances chromatin cleavage.

DNase I and DNase II both degrade NETs in vitro and in vivo, providing dual protection against excess NET formation (80). Mice genetically deficient in either DNase I or DNase II are protected against chronic neutrophilia induced by G-CSF. This indicates that in the absence of one DNase the other has the ability to compensate. However, if mice are both DNase I and DNase II deficient, mice die within 5 days. Mutations in both DNase I and DNase II are associated with autoimmune diseases (96, 97). Mice deficient in DNase I and DNase II spontaneously develop SLE (98–100).
TABLE 1 | Inflammatory mediators released by Neutrophil Extracellular Traps and potential inhibitors.

| Molecule Model of investigation | Inhibitor | References |
|--------------------------------|-----------|------------|
| **Inflammatory mediators released by Neutrophil extracellular traps** | | |
| Myeloperoxidase (MPO) Experimental AAV, clinical MPO | AZM198 | (59, 72) |
| Proteinase 3 (PR3) | | |
| Neutrophil Elastase (NE) Lung disease | Avellestat | (73–76) |
| Histones | Anti-histone antibody | (48) |
| DNA Animal models of AAV, Animal model of chronic neutrophilia | DNase 1 | (22, 80, 81) |
| mtDNA Animal model of EAE | SkQ1 | (68) |
| Reactive oxygen species (ROS) | | |
| High Mobility Group Box 1 (HMGB1) Animal models of sepsis, and IRI | Glycyrrhizin Gabexate mesilate HMGB1 specific ab | (82, 83) |
| **S100A8/A9** | SLE, T1D Clinical trials | Quinoline-3-carboxamide | (84, 85) |
| **Molecular targets in the initiation of NETS** | | |
| Peptidyl arginine deiminase 4 (PAD4) PTU induced AAV NET inhibition in Lupus prone MRL/lpr mice | CI amidine CI amidine | (86) |
| Peptidyl arginine deiminase 4 (PAD4) Experimental AAV | BB-CI amidine GSK484 | (88) |
| Gasdermin D Human and murine neutrophils | LDC7559 | (58) |
| Ripk1 Mouse NETs | Necrostatin (NEC) | (69) |
| Ripk3 Mouse model of AAV | Necrostatin (NEC1) | (22) |
| MLKL Mouse model of AAV | Necorsulfonamide | (22) |

TABLE 2 | Experimental evidence of the pathogenic role of NETs in AAV.

| Model | Experimental evidence | References |
|-------|-----------------------|------------|
| AAV PBMC and kidney biopsies | PR3-ANCA and MPO-ANCA stimulate NET formation ex vivo, glomerular NETs in AAV patient biopsies | (58) |
| AAV kidney biopsies | Extracellular MPO associated with glomerular NET formation, description of macrophage extracellular traps | (59) |
| AAV PBMCs | AAV patient neutrophils more likely to spontaneously NET than healthy controls | (62) |
| Animal model of AAV | NET formation can be inhibited by blocking the Necroptosis pathway | (22) |
| Animal model of AAV | NETs transfer neutrophil antigens in AAV | (41) |
| AAV PBMCs | NET formation can occur independent of ANCA, and complement pathway. | (62, 64) |
| AAV serum with healthy donor neutrophils | AAV NETs distinct morphology compare to SLE NETs | (65) |
| AAV Case Reports | NETs present in glomerul of biopsy | (60, 61) |
| PTU induced animal model of AAV | Cl amidine prevented MPO-ANCA production | (86) |
| PTU induced Wistar-Kyoto Rat model of AAV | Pharmaceutical Immunoglobulins reduce NETs and attenuated MPO-AAV | (60) |
| Animal model of AAV | DNase I reduces NET formation and ameliorates AAV | (61) |
| Animal model of AAV | NE−/− mice are NET depleted and protected from development of AAV | (91) |
| Animal model of AAV | PAD4−/− mice have significantly less glomerular NETs and attenuated AAV | (68) |
| Animal model of AAV | PAD inhibitors BB-CI amidine and GSK484 inhibit NET formation and protect attenuate development of AAV | (68) |

DNase I, has been shown to be safe and tolerable in a clinical trial in lupus, although not effective in treating the disease possibly due to the heterogeneity of the disease pathogenesis in Lupus, and the disease progression not reliant on immunoreactivity to DNA alone. However, valuable information on the safety and side effects can be taken from the trial, and applied to other forms of autoimmunity where extracellular DNA may play more of an injurious role (101).

Experimental evidence indicates that DNase I is therapeutic in two different models of ANCA vasculitis. Schreiber et al. demonstrated in a model of AAV that DNase I prevents ANCA induced NET formation, glomerular injury and protects mice from development of disease. MPO-ANCA activated NETs incubated with endothelial cells in vitro increased albumin permeability, which pre-treatment with DNase I prevented (22). Our own laboratory has shown that DNase I prevents the
development of AAV, through a reduction in ecDNA released during cell death, reduced NET formation and an associated decrease in the deposition of the autoantigen MPO. DNase I is able to reduce autoimmunity to MPO with a reduced number of MPO specific lymphocytes (IL17a and IFNγ) in the draining lymph nodes and an increase in the number of MPO specific T regulatory cells, suggesting that DNase I may have an immunomodulatory role. DNase I given at the time of antigen presentation reduced the numbers of CD11c positive DCs, and activation markers MHCI, CD40, CD80, CD86, and the numbers of activated CD4+ CD69+ T cells (81).

Treatment with DNase I is not without difficulties. To achieve a therapeutic benefit in animal models of AAV, DNase I is administered intravenously twice daily to combat the short half-life (3–4 h) of DNase I in the circulation (22, 81). Recombinant DNase I is rapidly inactivated by G actin therefore the benefits of an inhaled actin resistant DNase is being currently investigated in Phase I and II clinical trials for cystic fibrosis patients (NCT02605590, NCT02722122). Other avenues to combat the limited half-life of DNase I in the circulation involve using gene delivery vectors derived from adeno-associated virus vectors (AAvec). AAvec would overcome the critical issue of the short half-life of the enzyme to provide a “one shot” therapeutic for SLE and ANCA-vasculitis through continuous delivery of DNase I. AAvec technology has already been used successfully to treat blindness, clotting disorders, and neuromuscular disease in humans (102). Over expression of both DNase I and DNase I3 protein with pLIVE plasmids enables the liver to produce long lasting over expression of both proteins in mice. In a model of sepsis in DNase 1−/− and DNase I3−− mice, plasmid expression of DNase I and DNase I3 restores endogenous circulating levels of both types of DNase and prevents vascular occlusion from NETosis in a model of chronic neutrophilia (80).

DNase I coated melanin-like nanospheres have been used successfully to control NET dysregulation in a model of sepsis (103). To circumvent the relative short half-life of DNase I in the circulation bare bioinspired melanin-like nanospheres (bMNSs) are coated with polydopamine which immobilizes DNase I on the surface of the bMNSs. The DNase I bMNSs retain biological activity for 36 h. Intravenous injection of DNase I bMNSs significantly reduced NETosis, extracellular DNA levels, neutrophil counts, reduced MPO and NE activity, and proinflammatory cytokines in a murine model of sepsis. Mice given DNase I bMNSs had improved survival rates compared to mice given endogenous DNase I.

In addition to clearing NET DNA DNase I can clear DNA from other types of cell death where DNA is released into the extracellular environment such as apoptosis, necrosis, and pyroptosis. One limitation of DNase I is that it only dismantles formed NETs. Some NET remnants (histones and proteases) are left behind in vessel walls (104). DNase I as adjunctive therapy may allow reduction in the dose of currently used effective drugs particularly steroids, where high dose related side effects are common.

### Neutrophil Elastase Inhibitors

The role of neutrophil elastase (NE) as a major constituent of NETs is well-accepted however the role of NE in instigating NETosis is controversial. NE was first shown in 2010 to work synergistically with MPO to break down the nuclear envelope and help cleave histones as discussed in a previous section (29). These findings were confounded when it was found that NE−/− mice were able to form NETs in a model of deep vein thrombosis, putting into dispute the role of NE in forming NETs (105). Mice with a genetic deficiency in NE only had a modest reduction in NET formation compared to WT controls when ionomycin was used to stimulate NET formation. The conflict in these results suggests that NE plays a different role in instigating NETosis dependent on the stimulus. It is also possible in the absence of NE another protease takes over the role of regulation of NETosis. Recently it has been shown that GSDMD and NE work synergistically to break down the nuclear envelope and the outer cell membrane during NETosis highlighting again the importance of NE in NETosis and its relevance as a therapeutic target, both in instigating NETs and neutralizing once it has been exteriorized thorough NETosis (36).

Two promising candidates for neutrophil elastase inhibitors are Alvelestat and BAY 85-8501, both have been shown to be safe and tolerable in clinical trials for the treatment of airway diseases so is poised for clinical translation to target NETosis in AAV.

Alvelestat (AZD9668), is a 3rd generation neutrophil elastase inhibitor which is reversible and highly selective for Neutrophil Elastase and to a lesser extent PR3 (77). It has been utilized in Phase II clinical trials for the treatment of airway diseases at a dose of 60 mg b.i.d (twice daily) including cystic fibrosis (73), chronic obstructive pulmonary disease (74), and bronchiectasis (75). Alvelestat has been effective in inhibiting NETs in a model of acute lung injury/acute respiratory distress syndrome in mice and significantly reducing the inflammatory response (76).

BAY 85-8501 is a 5th generation neutrophil elastase inhibitor with potency similar to that of endogenous antiptroproteases, it has improved metabolic stability over the previous generation of inhibitors with an improved half-life. Phase I clinical trials with healthy males showed that a dose of up to 1 mg is well-tolerated with no evidence of adverse reactions (78). Phase II clinical trials have shown Bay 85-8501 to be safe for the treatment of non-cystic fibrosis bronchiectasis (79), and bronchiectasis (75). BAY 85-8501 reduces human primary neutrophil NET formation in vitro when stimulated with PMA (36). Based on the results of the safety profile of BAY 85-8501 and the in vitro capability of inhibiting NET formation, it is a promising candidate to block NET formation in AAV.

Inhibition of NE raises the possibility that host defense will be compromised. This is minimized with the use of the most recent generation of NE inhibitors as the inhibitors are reversible and have been shown to be dose dependent in ex vivo blood zymosan assays of neutrophils to determine the phagocytosis capability after use of the NE inhibitors (77). Of clinical relevance is preliminary data that they can inhibit NE activity to a level that has clinical benefit (between 50 and 90%) but does not
reduce the innate capacity of neutrophils to engulf and kill bacteria (77).

Our laboratory has shown that neutrophil elastase knock mice (Elane−/−) are protected from the development of murine MPO-AAV with a significant reduction in albuminuria/creatinine ratio, glomerular segmental necrosis, glomerular NETs and associated MPO deposition, recruitment of glomerular CD4+ T cells, macrophages and neutrophils (91). Both Alvelestat and BAY 85-8501 have been used to inhibit NETs in a model of MPO-AAV with favorable results. Daily administration of the NE inhibitors via oral gavage reduced glomerular injury, recruitment of glomerular CD4 T cells, CD8 T cells, macrophages and neutrophils. Glomerular NET accumulation and MPO deposition was significantly reduced. ANCA was significantly reduced in the BAY 85-8501 treated mice but not in the Alvelestat treated mice.

Collectively these experimental results demonstrate that NE inhibition is protective in experimental MPO-AAV. Favorable results from clinical trials in terms of safety and efficacy are encouraging for the investigation of clinical translation of Alvelestat and BAY 85-8501 for the treatment of MPO-ANCA-GN.

CONCLUDING REMARKS

Current treatment for AAV is suboptimal with unavoidable adverse effects. A targeted more specific treatment is required. NETs are a common feature within glomeruli of kidneys from MPO-AAV patients. The key autoantigens in AAV MPO and PR3 are released during NET formation along with other potential injurious molecules that cause direct injury to glomerular endothelial cells. Therapeutically targeting NETs will prevent the release of these autoantigens, reducing glomerular damage, with the potential to ameliorate the progression of AAV.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

This work was funded by National Health Research and Medical Council (Grant Number: 2001325).

REFERENCES

1. Arimura Y, Muso E, Fujimoto S, Hasegawa M, Kaname S, Usui J, et al. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol. (2016) 20:322–41. doi: 10.1007/s10157-015-1218-8
2. Greenhall GH, Salama AD. What is new in the management of rapidly progressive glomerulonephritis? Clin Kidney J. (2015) 8:143–50. doi: 10.1093/ckj/sfv008
3. Ball GV. The history of ANCA-associated vasculitis. Rheum Dis Clin North Am. (2010) 36:439–46. doi: 10.1016/j.rdc.2010.05.004
4. Hamour S, Salama AD, Pusey CD. Management of ANCA-associated vasculitis: current trends and future prospects. Ther Clin Risk Manag. (2010) 6:253–64. doi: 10.2147/TCRM.S6112
5. Jayne D. Review article: Progress of treatment in ANCA-associated vasculitis. Nephrology. (2009) 14:42–8. doi: 10.1111/j.1440-1797.2009.01010.x
6. Morgan MD, Harper L, Williams J, Savage C. Anti-neutrophil cytoplasm-associated glomerulonephritis. J Am Soc Nephrol. (2006) 17:1224–34. doi: 10.1681/ASN.2005080882
7. Hiemstra TF, Walsh M, Mah A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. (2010) 304:2381–8. doi: 10.1001/jama.2010.1658
8. Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. (2014) 25:225–31. doi: 10.1681/ASN.2013020143
9. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA. (1990) 87:1115–9. doi: 10.1073/pnas.87.11.4115
10. Brouwer E, Huitema MG, Mulder AH, Heeringa P, van Goor H, Tervaert JW, et al. Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney Int. (1994) 45:1120–31. doi: 10.1038/ki.1994.149
11. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. (2002) 110:955–63. doi: 10.1172/JCI1215918
12. Xiao H, Heeringa P, Liu Z, Huugen D, Hu P, Maeda N, et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol. (2005) 167:39–45. doi: 10.1016/S0002-9440(10)62951-3
13. Porges AJ, Redecha PB, Kimberly WT, Csernok E, Gross WL, Kimberly RP. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol. (1994) 153:1271–80.
14. Kocher M, Edberg JC, Fleit HB, Kimberly RP. Antineutrophil cytoplasmic antibodies preferentially engage Fc gammaRIIIb on human neutrophils. J Immunol. (1998) 161:6909–14.
15. Kettritz R, Jennette JC, Falk RJ. Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J Am Soc Nephrol. (1997) 8:386–94.
16. Dick J, Gan PY, Ford SL, Odobasic D, Alikhan MA, Loosen SH, et al. C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis. Kidney Int. (2018) 93:615–25. doi: 10.1016/j.kint.2017.09.018
17. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. (2007) 170:52–64. doi: 10.2353/ajpath.2007.060573
18. Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol. (2009) 20:289–98. doi: 10.1681/ASN.2008050497
19. Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. (2017) 28:2756–67. doi: 10.1681/ASN.2016111179
20. Fiers W, Beyaert R, Declercq W, Vandenabeele P. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene. (1999) 18:7719–30. doi: 10.1038/sj.onc.1203249
21. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature. (2015) 517:311–20. doi: 10.1038/nature14191
22. Schreiber A, Rousselle A, Becker FU, von Massenhausen A, Linkermann A, Kettritz R. Necroptosis controls NET generation and mediates complement activation, endothelial damage, and autoimmune vasculitis. Proc Natl Acad Sci USA. (2017) 114:E9618–25. doi: 10.1073/pnas.1708247114
23. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. *Science.* (2004) 303:1532–5. doi: 10.1126/science.1092385

24. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, et al. Novel cell death program leads to neutrophil extracellular traps. *J Cell Biol.* (2007) 176:231–41. doi: 10.1083/jcb.200606027

25. Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, Van Venrooj WJ, Klareksog L, et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. *Arthritis Res Ther.* (2005) 7:R45–67. doi: 10.1186/ar1697

26. Neeli I, Khan SN, Radic M. Histone deimination as a response to inflammatory stimuli in neutrophils. *J Immunol.* (2008) 180:1895–902. doi: 10.4049/jimmunol.180.3.1895

27. Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. *J Cell Biol.* (2009) 184:205–23. doi: 10.1083/jcb.200806072

28. Li P, Mi L, Lindberg M, Rosen H, Winterbourn CC, Nauseef W. Myeloperoxidase: a front-line defender against phagocytosed microorganisms. *J Leukoc Biol.* (2013) 93:185–98. doi: 10.1189/jlb.0712349

29. Bjornsdottir H, Welin A, Michaelsson E, Osla V, Berg S, Christenson K, et al. Neutrophil NET formation is regulated from the inside by myeloperoxidase-. Metzler KD, Goosmann C, Lubojemska A, Zychlinsky A, Papayannopoulos V. A myeloperoxidase-containing complex regulates neutrophil elastase release and actin dynamics during NETosis. *Cell Rep.* (2014) 8:883–96. doi: 10.1016/j.celrep.2014.06.044

30. Klebanoff SJ, Kettle AJ, Rosen H, Winterbourn CC, Nauseef WM. Myeloperoxidase: a front-line defender against phagocytosed microorganisms. *J Leukoc Biol.* (2013) 93:185–98. doi: 10.1189/jlb.0712349

31. Metzler KD, Goosmann C, Lubojemska A, Zychlinsky A, Papayannopoulos V. A myeloperoxidase-containing complex regulates neutrophil elastase release and actin dynamics during NETosis. *Cell Rep.* (2014) 8:883–96. doi: 10.1016/j.celrep.2014.06.044

32. Parker H, Dragunow M, Hampton MB, Kettle AJ, Winterbourn CC. Requirements for NADPH oxidase and myeloperoxidase in neutrophil extracellular trap formation depend on the stimulus. *J Leukoc Biol.* (2012) 92:841–9. doi: 10.1189/jlb.1211601

33. Bergbaek T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. *Nat Rev Microbiol.* (2009) 7:99–109. doi: 10.1038/nrmicro2070

34. Sollberger G, Choidas A, Burn GL, Habenberger P, Di Lucrezia R, Kordes S, et al. Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. *Sci Immunol.* (2015) 10.4049/jimmunol.1202733

35. Sollberger G, Choidas A, Burn GL, Habenberger P, Di Lucrezia R, Kordes S, et al. Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. *Sci Immunol.* (2015) 7:99–109. doi: 10.1126/sciimmunol.aar6689

36. Chen KW, Monteleone M, Boucher D, Sollberger G, Ramnath D, Condon ND, et al. Noncanonical inflammasome signaling elicits gasdermin D-dependent neutrophil extracellular traps. *Sci Immunol.* (2018) 3:1–12. doi: 10.1126/sciimmunol.aar6689

37. Hakkim A, Fuchs TA, Martinez NE, Hess S, Prinz H, Zychlinsky A, et al. Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. *Nat Chem Biol.* (2011) 7:99–109. doi: 10.1038/nchembio.496

38. Desai J, Kumar SV, Mulay SR, Konrad L, Romodi S, Schauer C, et al. PMA and crystal-induced neutrophil extracellular trap formation involves RIPK1-RIPK3-MLK1 signaling. *Eur J Immunol.* (2016) 46:223–9. doi: 10.1002/eji.201545605

39. Amini P, Stojkov D, Wang X, Wicki S, Kaufmann T, Wong WW, et al. NET formation can occur independently of RIPK3 and MLK1 signaling. *Eur J Immunol.* (2016) 46:178–84. doi: 10.1002/eji.201546515

40. Sangaletti S, Tripodo C, Chiiodoni C, Guarnotta C, Cappetti B, Casalini P, et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. *Blood.* (2012) 120:3007–18. doi: 10.1182/blood-2012-03-416156

41. O’Sullivan KM, Lo CY, Summers SA, Elgass KD, McMillan PJ, Longano A, et al. Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis. *Kidney Int.* (2015) 88:1030–46. doi: 10.1016/j.kisup.2015.202
60. Yoshida M, Sasaki M, Sugisaki K, Yagamachi Y, Yamada M. Neutrophil extracellular trap components in fibrinoid necrosis of the kidney with myeloperoxidase-ANCA-associated vasculitis. Clin Kidney J. (2013) 6:308–12. doi: 10.1093/ckj/sfs048

61. Nakazawa D, Tomaru U, Yamamoto C, Jodo S, Ishizu A. Abundant neutrophil extracellular traps in thrombi of patient with microscopic polyangiitis. Front Immunol. (2012) 3:333. doi: 10.3389/fimmu.2012.00333

62. Soderberg D, Kurz T, Motamedi A, Hellmark T, Eriksson P, Segelmark M. Increased levels of neutrophil extracellular trap remnants in the circulation of patients with small vessel vasculitis, but an inverse correlation to anti-neutrophil cytoplasmic antibodies during remission. Rheumatology. (2015) 54:2085–94. doi: 10.1093/rheumatology/kev217

63. Wang H, Sha L, Ma TT, Zhang LX, Chen M, Zhao MH. Circulating level of neutrophil extracellular traps is not a useful biomarker for assessing disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. PLoS ONE. (2016) 11:e0148197. doi: 10.1371/journal.pone.0148197

64. Kraaij T, Kamerling SWA, van Dam LS, Bakker JA, Bajema JM, Page T, et al. Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. Kidney Int. (2018) 94:1349–49. doi: 10.1016/j.kint.2018.01.013

65. van Dam LS, Kraaij T, Kamerling SWA, Bakker JA, Scherer UH, Rabelink TJ, et al. Intrinsically distinct role of neutrophil extracellular trap formation in antineutrophil cytoplasmic antibody-associated vasculitis compared to systemic lupus erythematosus. Arthritis Rheumatol. (2019) 71:2047–58. doi: 10.1002/art.41047

66. Yousefi S, Mihalache C, Kozlowski E, Schmid I, Simon HU. Viable lymphocytes eject interferogenic mitochondrial DNA webs in response to inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respir Med. (2015) 56:86–93. doi: 10.1016/j.rupmed.2019.03.009

67. O’Sullivan KM GP, Kitching AR, Holdsworth SR. Deoxyribonuclease I reduces glomerular injury and modulates antimyeloperoxidase autoimmunity in experimental anti myeloperoxidase glomerulonephritis. Rheumatology. (2017) 56:WS6–3. doi: 10.1093/rheumatology/kex120

68. Gong G, Xiang L, Yuan L, Hu L, Wu W, Cai L, et al. Protective effect of glycyrhrizin, a direct HMGB1 inhibitor, on focal cerebral ischemia/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats. PLoS ONE. (2014) 9:e89450. doi: 10.1371/journal.pone.0089450

69. Musunuce D, Boviello GN, Montesarchio D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther. (2014) 141:347–57. doi: 10.1016/j.pharmthera.2013.11.001

70. Coutu R, Landais P, Rosilio M, Johnsen C, Lahouli N, Chatelet P, et al. Low dose lomindine in Type 1 juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia. (1998) 41:1040–6. doi: 10.1002/1521-4141(199804)41:4<1040::AID-DIA970>3.0.CO;2-L

71. Bengtsso AA, Sturfelt G, Loo C, Ronnblom L, van Vollenhoven RF, Axelsson B, et al. Pharmacokinetics, tolerability, and preliminary efficacy of paximomidou (ARR-215757), a new quinolone-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Arthritis Rheum. (2012) 64:1579–88. doi: 10.1002/art.33393

72. Kusunoki Y, Nakazawa D, Shida H, Hattanda F, Miyoishi A, Masuda S, et al. Peptidylarginine deiminase inhibitor suppresses neutrophil extracellular trap formation and MPO-ANCA production. Front Immunol. (2017) 8:2227. doi: 10.3389/fimmu.2016.00227

73. Knight JS, Subramanian V, O’Dell AA, Yalavarthi S, Zhao W, Smith CK, et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis. (2015) 74:2199–206. doi: 10.1136/annrheumdis-2014-203563

74. O’Sullivan KM GP, Kitching AR, Holdsworth SR. Inhibition of peptidylarginine deiminase 4 limits neutrophil extracellular trap formation and inflammation in experimental anti MPO-ANCA glomerulonephritis. Rheumatology. (2019) 58:90–1. doi: 10.1093/rheumatology/kez061.024

75. D’Cruz AA, Speir M, Bliss-Moreau M, Dietrich S, Wang S, Chen AA, et al. The pseudokinase MLKL activates PAD4-dependent NET formation in necrotic neutrophils. Sci Signal. (2018) 11:1–1. doi: 10.1126/scisignal.aao1716

76. Uozumi R, Iguchi R, Masuda S, Nishibata Y, Nakazawa D, Tomaru U, et al. Antibacterial Peptidylarginine deiminase inhibitors reduce neutrophil extracellular trap formation and ameliorate the development of MPO-ANCA-associated vasculitis. Mod Rheumatol. (2020) 30:544–50. doi: 10.1080/14397959.2019.1602292

77. O’Sullivan KM GP, Kitching AR, Holdsworth SR. Neutrophil elastase-deficient mice are protected from experimental myeloperoxidase anti-neutrophil cytoplasmic antibody vasculitis. J Am Soc Nephrol. (2019) 30:912.

78. Knight JS, Luo W, O’Dell AA, Yalavarthi S, Zhao W, Smith CK, et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis. (2015) 74:2199–206. doi: 10.1136/annrheumdis-2014-203563

79. O’Sullivan KM GP, Kitching AR, Holdsworth SR. Neutrophil elastase-deficient mice are protected from experimental myeloperoxidase anti-neutrophil cytoplasmic antibody vasculitis. J Am Soc Nephrol. (2019) 30:912.

80. Li H, Zhou X, Tan H, Hu Y, Zhang L, Liu S, et al. Neutrophil extracellular trap components contribute to the pathogenesis of acid-assembly-induced ALI/ARDS. Oncotarget. (2018) 9:1772–84. doi: 10.18632/oncotarget.22744
during the inflammatory response. Sci Adv. (2016) 2:e1501257. doi: 10.1126/sciadv.1501257

94. Kawalkowska J, Quirke AM, Ghari F, Davis S, Subramanian V, Thompson PR, et al. Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses. Sci Rep. (2016) 6:26430. doi: 10.1038/srep26430

95. Wong SL, Demers M, Martinod K, Gallant M, Wang Y, Goldfine AB, et al. Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. Nat Med. (2015) 21:815–9. doi: 10.1038/nm.3887

96. Al-Mayouf SM, Sunker A, Abdwani R, Abrawi SA, Almurshed F, Alhashmi N, et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet. (2011) 43:1186–8. doi: 10.1038/ng.975

97. Yasutomo K, Horisuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet. (2001) 28:313–4. doi: 10.1038/91070

98. Wilber A, O’Connor TP, Lu ML, Karimi A, Schneider MC. Dnase1l3 deficiency in lupus-prone MRL and NZB/W F1 mice. Clin Exp Immunol. (2003) 134:46–52. doi: 10.1046/j.1365-2249.2003.02267.x

99. Serpas L, Chan RWY, Jiang P, Ni M, Sun K, Rashidfarokhi A, et al. Dnase1l3 deletion causes aberrations in length and end-motif frequencies in plasma DNA. Proc Natl Acad Sci USA. (2019) 116:641–9. doi: 10.1073/pnas.1815031116

100. Sirisak V, Sally B, D’Agati V, Martinez-Ortiz W, Ozcakar ZB, David I, et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell. (2016) 166:88–101. doi: 10.1016/j.cell.2016.05.034

101. Davis JC Jr., Manzi S, Yarboto C, Rairie J, McNines I, et al. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus. (1999) 8:68–76. doi: 10.1191/096120399678847380

102. Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sanz MJ, et al. Gene therapy comes of age. Science. (2018) 359(6372). doi: 10.1126/science.aan4672

103. Park HI, Park W, Lee YY, Kim H, Seo HS, Choi DW, et al. Bioinspired DNase-I-coated melanin-like nanospheres for modulation of infection-associated NETosis dysregulation. Adv Sci. (2020) 7:2001940. doi: 10.1002/advs.202001940

104. Kolaczkowska E, Jenne CN, Surewaard BG, Thanabalasuriar A, Lee WY, Sanz MJ, et al. Molecular mechanisms of NET formation and degradation revealed by intravital imaging in the liver vasculature. Nat Commun. (2015) 6:6673. doi: 10.1038/ncomms7673

105. Martinod K, Witsch T, Farley K, Gallant M, Remold-O’Donnell E, Wagner DD. Neutrophil elastase-deficient mice form neutrophil extracellular traps in an experimental model of deep vein thrombosis. J Thromb Haemost. (2016) 14:551–8. doi: 10.1111/jth.13239

106. O’Sullivan KM GP, Kitching AR, Holdsworth SR (editor). Neutrophil elastase inhibition attenuates renal inflammation in experimental MPO-ANCA vasculitis. Australian and New Zealand Society of Nephrology Annual Scientific Meeting 2020; Tasmania Australia (Hobart: Virtual due to COVID-19).

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 O’Sullivan and Holdsworth. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.